MedPath

Clinical evaluation of dried blood spots for the determination of ribociclib blood levels

Conditions
Borstkanker
10006291
Registration Number
NL-OMON48374
Lead Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
20
Inclusion Criteria

1. Age * 18 years;
2. Able to understand the written information and able to give informed consent;
3. Treated with ribociclib;
4. Able and willing to undergo a finger prick for dried blood spot sampling.

Exclusion Criteria

Unable to draw blood for study purposes.

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>To develop and validate a dried blood spot (DBS) method for determination of<br /><br>ribociclib.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>To characterize the pharmacokinetics of ribociclib.</p><br>
© Copyright 2025. All Rights Reserved by MedPath